ylliX - Online Advertising Network
Press Release

European Commission Approves Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy for Certain Patients With Esophageal Cancer or HER2-Negative Gastroesophageal Junction (GEJ) Adenocarcinoma

<script type="text/javascript" src="https://pppbr.com/bnr.php?section=Footer46860&pub=543549&format=728x90&ga=g&bg=1"></script>
<noscript><a href="https://yllix.com/publishers/543549" target="_blank"><img src="//ylx-aff.advertica-cdn.com/pub/728x90.png" style="border:none;margin:0;padding:0;vertical-align:baseline;" alt="ylliX - Online Advertising Network" /></a></noscript>

KENILWORTH, N.J.–(BUSINESS WIRE)—- $MRK #MRK–EC Approves Merck’s KEYTRUDA Plus Chemotherapy for Certain Patients With Esophageal Cancer or HER2-Negative GEJ Adenocarcinoma

...read full article on Business Wire

ylliX - Online Advertising Network